NDAORALCAPSULE, EXTENDED RELEASE
Approved
Nov 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
VERELAN PM (verapamil hydrochloride) by R-Pharm US is (l-type calcium channel blocker or calcium channel antagonist). First approved in 1998.
Drug data last refreshed 20h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Verelan PM is an extended-release oral capsule formulation of verapamil hydrochloride, a phenylalkylamine calcium channel blocker indicated for hypertension and angina. It works by selectively inhibiting L-type calcium channel influx into vascular smooth muscle and myocardial cells, reducing vascular resistance and cardiac contractility without altering serum calcium. The PM (bedtime) formulation delivers peak plasma levels in the morning, optimizing cardiovascular control during waking hours.
$0.12MPart D
LOE ApproachingProduct approaching loss of exclusivity with modest Part D penetration; brand team focus shifting toward lifecycle management and generic transition planning.
Mechanism of Action
(L-type calcium channel blocker or calcium channel antagonist). Verapamil exerts its pharmacologic effects by selectively inhibiting the transmembrane influx of ionic calcium into arterial smooth muscle as well as in conductile and contractile myocardial cells without altering serum calcium…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Verelan PM offers limited career growth opportunities as a LOE-approaching product with zero linked job postings. Roles remaining on this brand focus on defending market share, managing generic transition, and maintaining relationships with payers and providers as generic erosion accelerates.
Worked on VERELAN PM at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.